Which aspect must be described about the investigational product to ensure proper administration and traceability?

• A. The dosage and dosage regimen only
• B. The dosage form, packaging, and labeling
• C. The trial's budget and cost
• D. The medical history of investigators

Answer: (B)

In administering an investigational product, knowing how it is presented and identified is essential for safe use and traceability. The required description should cover the dosage form, packaging, and labeling because these elements together determine exactly what product is being given, how it should be prepared or administered, and how it should be stored. The dosage form tells you what the patient receives (pill, solution, injectable), while packaging and labeling provide critical identifiers like strength, lot or batch number, expiry date, and storage conditions. This combination enables accurate administration and allows you to trace every unit from supply through to the patient, which is crucial for safety monitoring and potential recalls. In contrast, budget or cost details do not affect how the product is administered or tracked, and the medical history of investigators does not contribute to product traceability.